COVID-19

Novavax’s 2024-2025 Formula COVID-19 Vaccine Receives Emergency Use Authorization in the US

Novavax’s 2024-2025 Formula COVID-19 Vaccine Receives Emergency Use Authorization in the US

Shots: Novavax’s COVID-19 vaccine, Adjuvanted (2024-2025 Formula) (NVX-CoV27...

AB Science Provides Update on P-II Trial Design of Masitinib for COVID-19

AB Science Provides Update on P-II Trial Design of Masitinib for COVID-19

Shots: The P-II (AB20001) trial was designed to assess masitinib + isoquercetin in...

Pfizer and BioNTech Report the CHMP’s Positive Opinion of Comirnaty JN.1 Vaccine for COVID-19

Pfizer and BioNTech Report the CHMP’s Positive Opinion of Comirnaty JN.1 Vaccine for COVID-19

Shots: The CHMP has granted positive opinion to Omicron JN.1-adapted COVID-19 vacc...

The EC Approves Biogen’s Tofidence (Biosimilar, Roactemra) for Treating Arthritis and COVID-19

The EC Approves Biogen’s Tofidence (Biosimilar, Roactemra) for Treating Arthritis and COVID-19

Shots: The EC has approved Tofidence (IV), a biosimilar version of Roactemra, to t...

AstraZeneca Reports Results from the P-III (SUPERNOVA) Study of Sipavibart to Prevent COVID-19 in Immunocompromised Patients

AstraZeneca Reports Results from the P-III (SUPERNOVA) Study of Sipavibart to Prevent COVID-19 in Immunocompromised Patients

Shots: The P-III (SUPERNOVA) study investigates the safety & efficacy of sipav...

Image